Benitec Biopharma Inc. — Form 10-Q Summary
Period: Fiscal third quarter and nine months ended March 31, 2023; filed May 15, 2023. The filing’s fiscal year ends June 30, so this is not a quarter ended in calendar 2022. Amounts below are U.S. dollars; financial statement figures are in thousands unless noted.
Business context and reporting period
Benitec is a development-stage biotechnology company developing genetic medicines using its DNA-directed RNA interference (ddRNAi) platform. Its lead candidate, BB-301, is an AAV-based “silence and replace” therapy in development for oculopharyngeal muscular dystrophy (OPMD). The company has no approved products and has not generated product-sale revenue; reported revenue is primarily licensing revenue.
Financial performance and liquidity
| Metric | Three months ended March 31, 2023 | Three months ended March 31, 2022 | Nine months ended March 31, 2023 | Nine months ended March 31, 2022 |
|---|---|---|---|---|
| Revenue | $54 | $48 | $68 | $73 |
| Research and development | $3,167 | $2,171 | $9,588 | $8,096 |
| General and administrative | $1,228 | $1,337 | $5,011 | $5,093 |
| Total operating expenses | $4,395 | $3,508 | $14,599 | $13,189 |
| Net loss | $(4,397) | $(3,275) | $(14,901) | $(13,141) |
| Net loss per share, basic and diluted | $(0.16) | $(0.40) | $(0.67) | $(1.61) |
- For the nine months, operating cash use was $13.9 million, up from $11.0 million a year earlier. Financing provided $16.0 million, principally from the September 2022 offering; foreign-exchange effects added $0.4 million. Cash, cash equivalents and restricted cash increased by $2.5 million to $6.565 million.
- At March 31, 2023, cash and cash equivalents were $6.551 million; total assets were $8.220 million, total liabilities $3.507 million, and stockholders’ equity $4.713 million. Current assets were $7.395 million and current liabilities $3.153 million.
- The company reported no borrowings or credit facility. Lease liabilities totaled $623,000, including $269,000 current and $354,000 non-current.
- Accumulated deficit was $163.2 million. The filing states that existing cash is insufficient to fund operations for the next 12 months without additional financing and that substantial doubt exists about the company’s ability to continue as a going concern.
Material changes versus comparable periods
- Nine-month revenue declined slightly, from $73,000 to $68,000, and remains immaterial relative to operating costs.
- Nine-month R&D expense rose $1.5 million, primarily reflecting BB-301 development, including the regulatory toxicology and assay-method work and continued GMP manufacturing and Natural History Study activities. Quarterly R&D increased to $3.2 million from $2.2 million.
- Nine-month net loss increased by $1.8 million. Quarterly net loss also widened, despite lower G&A, mainly as operating expenses increased and other income shifted to a loss.
- Cash rose from $4.1 million at June 30, 2022 to $6.6 million at March 31, 2023, principally due to the equity financing; this occurred alongside higher operating cash use.
- Shares outstanding increased from 8.17 million at June 30, 2022 to 27.98 million at March 31, 2023 following the September 2022 capital raise and exercise of pre-funded warrants. The reported loss per share is not directly comparable across periods because the weighted-average share count rose substantially.
Outlook, management commentary, and risks
- Financing: The September 2022 offering generated approximately $16.0 million net proceeds. The company said it expects ongoing losses and needs additional capital; future financing may be unavailable, costly, or dilutive and could require changes to development plans.
- BB-301: The company reported completion of the Beagle dog Pilot Dosing Study and positive interim tissue-transduction and gene-expression findings. These are preclinical results, not evidence of clinical efficacy. The Natural History Study began enrolling in January 2023. Management targeted BB-301 dosing and interim safety and efficacy disclosures in the second half of 2023; these are forward-looking objectives, not guarantees.
- Nasdaq listing: The company had not regained the $1.00 minimum bid-price requirement and received an additional compliance period through September 5, 2023. It could consider a reverse stock split, for which shareholders had authorized board discretion, but management then said it had no current plan to proceed. Failure to regain compliance could lead to delisting and impair trading liquidity and access to capital.
- Development and operating risks: Risks include clinical and regulatory uncertainty, dependence on collaborators and vendors, intellectual-property protection, competition, additional financing needs, and potential delays or cost increases. The filing discusses pandemic-related clinical-development delays and supply-chain challenges.
- The company reported no material legal proceedings. Management concluded disclosure controls and procedures were effective and reported no material change in internal control over financial reporting during the quarter.
- No specific revenue, earnings, or cash-flow guidance was provided. The filing anticipates continued operating losses and potentially increased development costs.
Important facts for investors to verify
- Whether the company obtained financing after March 31, 2023, and how long available funds can support its operating plan.
- Subsequent BB-301 trial progress, including actual dosing, enrollment, and clinical safety and efficacy data versus the stated second-half 2023 targets.
- Whether Benitec regained Nasdaq’s minimum bid-price compliance by the September 5, 2023 deadline, and whether any reverse split or other listing action followed.
- The potential dilution from the 39.9 million warrants outstanding at March 31, 2023, including Series 2 warrants exercisable at $0.66 per share, and any subsequent share or warrant issuance.
- Whether R&D spending, cash burn, accrued development costs, or trial timelines changed materially after quarter-end.